TY - JOUR
T1 - Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy
AU - Wu, Xifeng
AU - Ye, Yuanqing
AU - Rosell, Rafael
AU - Amos, Christopher I.
AU - Stewart, David J.
AU - Hildebrandt, Michelle A T
AU - Roth, Jack A.
AU - Minna, John D.
AU - Gu, Jian
AU - Lin, Jie
AU - Buch, Shama C.
AU - Nukui, Tomoko
AU - Ramirez Serrano, Jose Luis
AU - Taron, Miquel
AU - Cassidy, Adrian
AU - Lu, Charles
AU - Chang, Joe Y.
AU - Lippman, Scott M.
AU - Hong, Waun Ki
AU - Spitz, Margaret R.
AU - Romkes, Marjorie
AU - Yang, Ping
PY - 2011/5/18
Y1 - 2011/5/18
N2 - Background Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non-small cell lung cancer (NSCLC). Methods To identify genetic variants associated with poor overall survival in these patients, we conducted a genome-wide scan of 307 260 single-nucleotide polymorphisms (SNPs) in 327 advanced-stage NSCLC patients who received platinum-based chemotherapy with or without radiation at the University of Texas MD Anderson Cancer Center (the discovery population). A fast-track replication was performed for 315 patients from the Mayo Clinic followed by a second validation at the University of Pittsburgh in 420 patients enrolled in the Spanish Lung Cancer Group PLATAX clinical trial. A pooled analysis combining the Mayo Clinic and PLATAX populations or all three populations was also used to validate the results. We assessed the association of each SNP with overall survival by multivariable Cox proportional hazard regression analysis. All statistical tests were two-sided. Results SNP rs1878022 in the chemokine-like receptor 1 (CMKLR1) was statistically significantly associated with poor overall survival in the MD Anderson discovery population (hazard ratio [HR] of death = 1.59, 95% confidence interval [CI] = 1.32 to 1.92, P = 1.42 × 10-6), in the PLATAX clinical trial (HR of death = 1.23, 95% CI = 1.00 to 1.51, P =. 05), in the pooled Mayo Clinic and PLATAX validation (HR of death = 1.22, 95% CI = 1.06 to 1.40, P =. 005), and in pooled analysis of all three populations (HR of death = 1.33, 95% CI = 1.19 to 1.48, P = 5.13 × 10-7). Carrying a variant genotype of rs10937823 was associated with decreased overall survival (HR of death = 1.82, 95% CI = 1.42 to 2.33, P = 1.73 × 10-6) in the pooled MD Anderson and Mayo Clinic populations but not in the PLATAX trial patient population (HR of death = 0.96, 95% CI = 0.69 to 1.35). Conclusion These results have the potential to contribute to the future development of personalized chemotherapy treatments for individual NSCLC patients.
AB - Background Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non-small cell lung cancer (NSCLC). Methods To identify genetic variants associated with poor overall survival in these patients, we conducted a genome-wide scan of 307 260 single-nucleotide polymorphisms (SNPs) in 327 advanced-stage NSCLC patients who received platinum-based chemotherapy with or without radiation at the University of Texas MD Anderson Cancer Center (the discovery population). A fast-track replication was performed for 315 patients from the Mayo Clinic followed by a second validation at the University of Pittsburgh in 420 patients enrolled in the Spanish Lung Cancer Group PLATAX clinical trial. A pooled analysis combining the Mayo Clinic and PLATAX populations or all three populations was also used to validate the results. We assessed the association of each SNP with overall survival by multivariable Cox proportional hazard regression analysis. All statistical tests were two-sided. Results SNP rs1878022 in the chemokine-like receptor 1 (CMKLR1) was statistically significantly associated with poor overall survival in the MD Anderson discovery population (hazard ratio [HR] of death = 1.59, 95% confidence interval [CI] = 1.32 to 1.92, P = 1.42 × 10-6), in the PLATAX clinical trial (HR of death = 1.23, 95% CI = 1.00 to 1.51, P =. 05), in the pooled Mayo Clinic and PLATAX validation (HR of death = 1.22, 95% CI = 1.06 to 1.40, P =. 005), and in pooled analysis of all three populations (HR of death = 1.33, 95% CI = 1.19 to 1.48, P = 5.13 × 10-7). Carrying a variant genotype of rs10937823 was associated with decreased overall survival (HR of death = 1.82, 95% CI = 1.42 to 2.33, P = 1.73 × 10-6) in the pooled MD Anderson and Mayo Clinic populations but not in the PLATAX trial patient population (HR of death = 0.96, 95% CI = 0.69 to 1.35). Conclusion These results have the potential to contribute to the future development of personalized chemotherapy treatments for individual NSCLC patients.
UR - http://www.scopus.com/inward/record.url?scp=79957468312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957468312&partnerID=8YFLogxK
U2 - 10.1093/jnci/djr075
DO - 10.1093/jnci/djr075
M3 - Article
C2 - 21483023
AN - SCOPUS:79957468312
SN - 0027-8874
VL - 103
SP - 817
EP - 825
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 10
ER -